CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Coherus Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.96−0.03 (-3.16%)
Close on Oct 19, 2026
- Market cap
- $148.42M
- P/E (TTM)
- 0.7
- Dividend yield
- –
Coherus Oncology, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LOQTORZI | $13.61M | $11.80M | $12.36M | $11.17M | $9.96M | $7.35M | $7.52M | $5.83M | $3.79M | $1.99M | – | – | 95.1% | +36.7% |
| Other revenue | $694.00K | $507.00K | $388.00K | $402.00K | $295.00K | $251.00K | $211.00K | $220.00K | $6.51M | $320.00K | $118.00K | $204.00K | 4.9% | +135.3% |
| Total net product revenue | – | – | – | – | – | – | $53.93M | $70.55M | $58.47M | $76.74M | $91.41M | $74.36M | – | – |
| UDENYCA | – | – | – | – | – | – | $46.28M | $66.09M | $50.92M | $42.67M | $36.19M | $32.97M | – | – |
| CIMERLI | – | – | – | – | – | – | $100.00K | -$1.22M | $0 | $28.19M | $52.45M | $40.04M | – | – |
| YUSIMRY | – | – | – | – | – | – | $33.00K | -$152.00K | $3.77M | $3.89M | $2.21M | $1.36M | – | – |
By region
From the segment and revenue-disaggregation notes of Coherus Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.